Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Lung Cancer

Expert Opinion / Cases · March 21, 2022

Resectable Lung Adenocarcinoma — Yes to Immunotherapy, but When?

Written by
Michael J. Grant MD

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • José Ramón Villarreal

    Mar 25, 2022

    3

  • Thomas Ganim

    Mar 25, 2022

    #4

  • Mayer Gorbaty

    Mar 28, 2022

    4

  • José Ramón Villarreal

    Mar 28, 2022

    Opción 3

  • claudio sini

    May 17, 2022

    4

  • Louis Dupper

    Jul 27, 2022

    3

  • May 26, 2024

    Pending Moderator approval.
    Delete

Further Reading